HMS placeholder

Anthony George Letai, M.D., Ph.D.

Professor of Medicine
Publications View
Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release.
Authors: Authors: Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ.
Hum Mol Genet
View full abstract on Pubmed
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts.
Authors: Authors: Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A.
J Cell Biol
View full abstract on Pubmed
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
Authors: Authors: Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR.
Blood
View full abstract on Pubmed
Hiding from ABT-737 in lymph nodes.
Authors: Authors: Letai A.
Blood
View full abstract on Pubmed
Puma strikes Bax.
Authors: Authors: Letai A.
J Cell Biol
View full abstract on Pubmed
Control of mitochondrial apoptosis by the Bcl-2 family.
Authors: Authors: Brunelle JK, Letai A.
J Cell Sci
View full abstract on Pubmed
Mimicking the BH3 domain to kill cancer cells.
Authors: Authors: Ni Chonghaile T, Letai A.
Oncogene
View full abstract on Pubmed
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
Authors: Authors: Kutuk O, Letai A.
Cancer Res
View full abstract on Pubmed
BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals.
Authors: Authors: Jette CA, Flanagan AM, Ryan J, Pyati UJ, Carbonneau S, Stewart RA, Langenau DM, Look AT, Letai A.
Cell Death Differ
View full abstract on Pubmed
BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2.
Authors: Authors: Flanagan AM, Letai A.
Cell Death Differ
View full abstract on Pubmed